CO2021005178A2 - Anticuerpo monoclonal que se une específicamente al antígeno cd20 - Google Patents
Anticuerpo monoclonal que se une específicamente al antígeno cd20Info
- Publication number
- CO2021005178A2 CO2021005178A2 CONC2021/0005178A CO2021005178A CO2021005178A2 CO 2021005178 A2 CO2021005178 A2 CO 2021005178A2 CO 2021005178 A CO2021005178 A CO 2021005178A CO 2021005178 A2 CO2021005178 A2 CO 2021005178A2
- Authority
- CO
- Colombia
- Prior art keywords
- antigen
- specifically binds
- monoclonal antibody
- antibody
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a la biotecnología y proporciona un anticuerpo monoclonal que se une específicamente al antígeno CD20. La invención también se refiere a ADN que codifica dicho anticuerpo, los correspondientes vectores de expresión y métodos para su producción, al igual que métodos de tratamiento para emplear dicho anticuerpo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2018138510A RU2724469C2 (ru) | 2018-10-31 | 2018-10-31 | Моноклональное антитело, которое специфически связывается с cd20 |
PCT/RU2019/050205 WO2020091634A1 (ru) | 2018-10-31 | 2019-10-30 | Моноклональное антитело, которое специфически связывается с cd20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021005178A2 true CO2021005178A2 (es) | 2021-04-30 |
Family
ID=70462324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0005178A CO2021005178A2 (es) | 2018-10-31 | 2021-04-22 | Anticuerpo monoclonal que se une específicamente al antígeno cd20 |
Country Status (25)
Country | Link |
---|---|
US (1) | US20220089761A1 (es) |
EP (1) | EP3875486A4 (es) |
JP (1) | JP2022506430A (es) |
KR (1) | KR20210084604A (es) |
CN (1) | CN113272329A (es) |
AR (1) | AR116937A1 (es) |
AU (1) | AU2019373999A1 (es) |
BR (1) | BR112021008326A2 (es) |
CA (1) | CA3117486A1 (es) |
CL (1) | CL2021001104A1 (es) |
CO (1) | CO2021005178A2 (es) |
EA (1) | EA202191173A1 (es) |
EC (1) | ECSP21028958A (es) |
IL (1) | IL282742A (es) |
JO (1) | JOP20210100A1 (es) |
MA (1) | MA53186B2 (es) |
MX (1) | MX2021005033A (es) |
PE (1) | PE20211731A1 (es) |
PH (1) | PH12021550991A1 (es) |
RU (1) | RU2724469C2 (es) |
SG (1) | SG11202104248UA (es) |
TW (1) | TW202031682A (es) |
UY (1) | UY38432A (es) |
WO (1) | WO2020091634A1 (es) |
ZA (1) | ZA202102874B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024025440A1 (en) * | 2022-07-26 | 2024-02-01 | Joint Stock Company "Biocad" | Pharmaceutical composition of anti-cd20 antibody and use thereof |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
FI891226A (fi) | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
WO1990008187A1 (en) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
WO1990011294A1 (en) | 1989-03-21 | 1990-10-04 | The Immune Response Corporation | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
ATE161850T1 (de) | 1989-07-19 | 1998-01-15 | Connetics Corp | T-zell-rezeptor-peptide als heilmittel für autoimmune und bösartige krankheiten |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
EP0752248B1 (en) | 1992-11-13 | 2000-09-27 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
EP1519959B1 (en) * | 2002-02-14 | 2014-04-02 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
AU2011226858B2 (en) * | 2002-12-16 | 2015-01-22 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
BRPI0316779B1 (pt) | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
ES2322267T3 (es) | 2003-04-09 | 2009-06-18 | Genentech, Inc. | Terapia de una enfermedad autoinmunologica en un paciente que presenta una respuesta inadecuada a un inhibidor de tnf-alfa. |
DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
RU2489166C2 (ru) | 2006-04-09 | 2013-08-10 | Джинентех, Инк. | Применение антитела для лечения аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа |
US9175086B2 (en) * | 2010-02-10 | 2015-11-03 | Immunogen, Inc. | CD20 antibodies and uses thereof |
CN102190728B (zh) * | 2010-03-17 | 2014-07-02 | 永卓博济(上海)生物医药技术有限公司 | 一种人源化抗cd20单克隆抗体 |
-
2018
- 2018-10-31 RU RU2018138510A patent/RU2724469C2/ru active
-
2019
- 2019-10-29 TW TW108139053A patent/TW202031682A/zh unknown
- 2019-10-30 EA EA202191173A patent/EA202191173A1/ru unknown
- 2019-10-30 WO PCT/RU2019/050205 patent/WO2020091634A1/ru unknown
- 2019-10-30 SG SG11202104248UA patent/SG11202104248UA/en unknown
- 2019-10-30 JO JOP/2021/0100A patent/JOP20210100A1/ar unknown
- 2019-10-30 CN CN201980087511.2A patent/CN113272329A/zh active Pending
- 2019-10-30 AU AU2019373999A patent/AU2019373999A1/en active Pending
- 2019-10-30 BR BR112021008326-0A patent/BR112021008326A2/pt unknown
- 2019-10-30 JP JP2021523796A patent/JP2022506430A/ja active Pending
- 2019-10-30 US US17/288,234 patent/US20220089761A1/en active Pending
- 2019-10-30 MX MX2021005033A patent/MX2021005033A/es unknown
- 2019-10-30 EP EP19880700.0A patent/EP3875486A4/en active Pending
- 2019-10-30 MA MA53186A patent/MA53186B2/fr unknown
- 2019-10-30 CA CA3117486A patent/CA3117486A1/en active Pending
- 2019-10-30 UY UY0001038432A patent/UY38432A/es unknown
- 2019-10-30 PE PE2021000556A patent/PE20211731A1/es unknown
- 2019-10-30 KR KR1020217016587A patent/KR20210084604A/ko active Search and Examination
- 2019-10-31 AR ARP190103167A patent/AR116937A1/es unknown
-
2021
- 2021-04-22 EC ECSENADI202128958A patent/ECSP21028958A/es unknown
- 2021-04-22 CO CONC2021/0005178A patent/CO2021005178A2/es unknown
- 2021-04-28 IL IL282742A patent/IL282742A/en unknown
- 2021-04-28 CL CL2021001104A patent/CL2021001104A1/es unknown
- 2021-04-29 ZA ZA2021/02874A patent/ZA202102874B/en unknown
- 2021-04-30 PH PH12021550991A patent/PH12021550991A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2724469C2 (ru) | 2020-06-23 |
EA202191173A1 (ru) | 2021-07-28 |
MX2021005033A (es) | 2021-06-15 |
ZA202102874B (en) | 2022-06-29 |
TW202031682A (zh) | 2020-09-01 |
MA53186B2 (fr) | 2023-05-31 |
KR20210084604A (ko) | 2021-07-07 |
US20220089761A1 (en) | 2022-03-24 |
CN113272329A (zh) | 2021-08-17 |
MA53186A1 (fr) | 2022-02-28 |
CL2021001104A1 (es) | 2021-12-03 |
ECSP21028958A (es) | 2021-05-31 |
EP3875486A1 (en) | 2021-09-08 |
PE20211731A1 (es) | 2021-09-06 |
EP3875486A4 (en) | 2022-08-03 |
IL282742A (en) | 2021-06-30 |
JP2022506430A (ja) | 2022-01-17 |
JOP20210100A1 (ar) | 2023-01-30 |
AU2019373999A1 (en) | 2021-05-27 |
RU2018138510A3 (es) | 2020-04-30 |
BR112021008326A2 (pt) | 2021-08-31 |
AR116937A1 (es) | 2021-06-30 |
CA3117486A1 (en) | 2020-05-07 |
UY38432A (es) | 2020-05-29 |
WO2020091634A1 (ru) | 2020-05-07 |
PH12021550991A1 (en) | 2021-10-04 |
RU2018138510A (ru) | 2020-04-30 |
SG11202104248UA (en) | 2021-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023001092A1 (es) | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor | |
ECSP17054182A (es) | Anticuerpos anti-CD3, anticuerpos anti-CD123 y anticuerpos biespecíficos que se unen específicamente a CD3 y/o CD123 | |
ECSP20024555A (es) | Anticuerpos especificos para cd47 y pd-l1 | |
EA201792467A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
UY37683A (es) | Anticuerpo monoclonal anti-pd-l1 monoclonal | |
NI201400019A (es) | Anticuerpo anti-alfabetatcr | |
CO2021014153A2 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
PE20181199A1 (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano | |
CO2019010164A2 (es) | Anticuerpos que se unen a steap-1 | |
BR112021011529A2 (pt) | Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado | |
CL2021001104A1 (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 | |
CO2018010286A2 (es) | Método para la purificación de proteínas | |
ECSP20024551A (es) | ANTICUERPO MONOCLONAL PARA IL-5Ra | |
UY37915A (es) | Anticuerpos específicos para cd47 y pd-l1 |